Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:002240710 | Cervix | CC | regulation of cell-cell adhesion | 103/2311 | 448/18723 | 1.78e-10 | 2.87e-08 | 103 |
GO:004578510 | Cervix | CC | positive regulation of cell adhesion | 101/2311 | 437/18723 | 1.96e-10 | 3.08e-08 | 101 |
GO:00421108 | Cervix | CC | T cell activation | 107/2311 | 487/18723 | 1.24e-09 | 1.46e-07 | 107 |
GO:00508638 | Cervix | CC | regulation of T cell activation | 80/2311 | 329/18723 | 1.28e-09 | 1.47e-07 | 80 |
GO:00071598 | Cervix | CC | leukocyte cell-cell adhesion | 85/2311 | 371/18723 | 8.27e-09 | 7.07e-07 | 85 |
GO:00071626 | Cervix | CC | negative regulation of cell adhesion | 72/2311 | 303/18723 | 2.36e-08 | 1.70e-06 | 72 |
GO:00026837 | Cervix | CC | negative regulation of immune system process | 94/2311 | 434/18723 | 2.63e-08 | 1.87e-06 | 94 |
GO:19030378 | Cervix | CC | regulation of leukocyte cell-cell adhesion | 77/2311 | 336/18723 | 4.08e-08 | 2.54e-06 | 77 |
GO:003009910 | Cervix | CC | myeloid cell differentiation | 83/2311 | 381/18723 | 1.31e-07 | 6.42e-06 | 83 |
GO:00002097 | Cervix | CC | protein polyubiquitination | 58/2311 | 236/18723 | 1.57e-07 | 7.41e-06 | 58 |
GO:190370610 | Cervix | CC | regulation of hemopoiesis | 80/2311 | 367/18723 | 2.14e-07 | 9.55e-06 | 80 |
GO:00224084 | Cervix | CC | negative regulation of cell-cell adhesion | 48/2311 | 196/18723 | 1.99e-06 | 6.18e-05 | 48 |
GO:19021056 | Cervix | CC | regulation of leukocyte differentiation | 61/2311 | 279/18723 | 5.16e-06 | 1.29e-04 | 61 |
GO:00224099 | Cervix | CC | positive regulation of cell-cell adhesion | 61/2311 | 284/18723 | 9.30e-06 | 2.11e-04 | 61 |
GO:19021064 | Cervix | CC | negative regulation of leukocyte differentiation | 29/2311 | 102/18723 | 1.02e-05 | 2.29e-04 | 29 |
GO:0051250 | Cervix | CC | negative regulation of lymphocyte activation | 39/2311 | 157/18723 | 1.23e-05 | 2.57e-04 | 39 |
GO:19030397 | Cervix | CC | positive regulation of leukocyte cell-cell adhesion | 53/2311 | 239/18723 | 1.37e-05 | 2.74e-04 | 53 |
GO:00508708 | Cervix | CC | positive regulation of T cell activation | 49/2311 | 216/18723 | 1.51e-05 | 2.97e-04 | 49 |
GO:19037074 | Cervix | CC | negative regulation of hemopoiesis | 29/2311 | 106/18723 | 2.29e-05 | 4.01e-04 | 29 |
GO:0002695 | Cervix | CC | negative regulation of leukocyte activation | 43/2311 | 187/18723 | 3.47e-05 | 5.60e-04 | 43 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CBFB | SNV | Missense_Mutation | | c.394N>A | p.Ala132Thr | p.A132T | Q13951 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-A2-A0EO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
CBFB | SNV | Missense_Mutation | | c.201N>T | p.Gln67His | p.Q67H | Q13951 | protein_coding | tolerated(0.55) | probably_damaging(0.962) | TCGA-A8-A08S-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
CBFB | SNV | Missense_Mutation | novel | c.220N>A | p.Gln74Lys | p.Q74K | Q13951 | protein_coding | tolerated(0.74) | benign(0.031) | TCGA-A8-A08T-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
CBFB | SNV | Missense_Mutation | | c.362N>A | p.Gly121Asp | p.G121D | Q13951 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A8-A096-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CBFB | SNV | Missense_Mutation | | c.188A>T | p.Asn63Ile | p.N63I | Q13951 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CBFB | SNV | Missense_Mutation | | c.296N>T | p.Ala99Val | p.A99V | Q13951 | protein_coding | tolerated(0.16) | probably_damaging(0.961) | TCGA-B6-A0RN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CBFB | SNV | Missense_Mutation | | c.311N>G | p.Asn104Ser | p.N104S | Q13951 | protein_coding | deleterious(0) | possibly_damaging(0.819) | TCGA-BH-A0EA-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | CR |
CBFB | SNV | Missense_Mutation | | c.306N>G | p.Ile102Met | p.I102M | Q13951 | protein_coding | deleterious(0) | probably_damaging(0.944) | TCGA-BH-A1FL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CBFB | SNV | Missense_Mutation | | c.104N>C | p.Arg35Pro | p.R35P | Q13951 | protein_coding | deleterious(0) | benign(0.01) | TCGA-E2-A15C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
CBFB | SNV | Missense_Mutation | | c.167N>G | p.Ala56Gly | p.A56G | Q13951 | protein_coding | deleterious(0.01) | probably_damaging(0.966) | TCGA-E2-A1L9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
865 | CBFB | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | CYTARABINE HYDROCHLORIDE | CYTARABINE HYDROCHLORIDE | |
865 | CBFB | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | PURPUROGALLIN | PURPUROGALLIN | |
865 | CBFB | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | PHENANTHROLINE | PHENANTHROLINE | |
865 | CBFB | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | CY-208243 | CHEMBL313737 | |
865 | CBFB | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | FUSARIC ACID | FUSARIC ACID | |
865 | CBFB | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | PYROGALLOL | PYROGALLOL | |
865 | CBFB | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | APOMORPHINE HYDROCHLORIDE HEMIHYDRATE | APOMORPHINE HYDROCHLORIDE HEMIHYDRATE | |
865 | CBFB | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | QUINOLINIC ACID | QUINOLINIC ACID | |
865 | CBFB | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | L-NOREPINEPHRINE | L-NOREPINEPHRINE | |
865 | CBFB | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | IRIGINOL HEXAACEATATE | IRIGINOL HEXAACEATATE | |